HTG Molecular Diagnostics Inc (NASDAQ:HTGM), one of the industry leaders in the provision of reagents, instruments, and services for molecular profiling applications has made the much awaited announcement. It has finally unveiled its new HTG EdgeSeq PATH Assay for sale in Europe and in the U.S.
The HTG EdgeSeq PATH Assay steps in the scene as the perfect complement for the traditional immunohistochemistry (IHC) testing. The various investigators will from now onwards be in a position to properly asses mRNA expression of large numbers of biomarkers during those instances where there will be a shortage of the formalin-fixed, paraffin-embedded (FFPE) sample. Some trusted sources affirm that Assay has been manufactured to help detect up to 470 mRNA targets, a figure that IHC used to asses.
According to Yahoo, HTG Molecular Diagnostics Inc believes the trend toward smaller and less invasive biopsy methods is critical towards helping it benefit from a larger market share of the new HTG EdgeSeq PATH Assay. As a matter of fact, it will need a lot of information to succeed in its quest.
The Chief Executive Officer in a press conference said, “We expect this product to enable simple and cost effective retrospective studies, which, ultimately, could lead to new GEP-based diagnostic, prognostic and predictive classifiers in solid tumors and clinical IHC-replacement products, and an estimated $1.5 billion market opportunity.”
A spokeswoman representing the company has said that customers mean absolutely everything for their business. They will do all within their means to serve them with top end services and products. She added that the main reason behind them designing assay lay in fact that their customers would be in position to profile small tissue biopsies in a more elaborate way. The company hopes that the additional GEP information will help much towards helping it make major advancements in research. Over the years, it has remained much dedicated to providing top end patient care.
